TRAILR-1 expression levels among Responders and Non Responders to IFN beta therapy, in different PBMC subsets.

<p>Expression level is represented as relative expression compared to the reference gene GAPDH, using the ΔΔCt method. TRAILR-1 expression levels between responder and non responder patients to IFN beta therapy in each of the assessed cell subsets were compared by a Mann Whitney test.</p

Molecular dynamics simulations of Glu228Ala SNP in TRAILR-1.

<p>A and C corresponds to the superimposed structures of the 50s and 90s loops respectively in the initial (green) and final (orange) model of the <b>wild type</b> of TRAILR-1 (Glutamatic acid at position 228). B and D corresponds to the superimposed structures of the loops in the initial (green) and final (brown) model of the <b>mutant type</b> of TRAILR-1 (Alanine at position 228).</p

Alignment and secondary structure homology between TRAILR-2 and TRAILR-1.

<p>The high conservation in the amino acid sequence and secondary structure of both receptors has allowed us to use a slightly modified structure of TRAILR-2 in the molecular modelling.</p

TRAILR-1 expression levels in MS patients stratified by the rs20576 genotype, in different PBMC subsets.

<p>Expression level is represented as relative expression compared to the reference gene GAPDH, using the ΔΔCt method. TRAILR-1 expression levels between patients with A/− and CC genotypes were compared by a Mann Whitney test.</p

Demographic and clinical characteristics of the MS patients.

<p>Quantitative data are presented as mean ± standard deviation (minimum–maximum).</p

Genotypes frequencies for rs20576 according to response to IFN beta in all patients and NABs-free patients.

<p>P values and Odds Ratios under a recessive model. Abbreviations: A/−: wild type and heterozygous genotypes; OR (95% CI) = odds ratio with confidence interval at 95%.</p